By proceeding, you agree to our Terms of Use and Privacy Policy.
Manal F. Abdelmalek, MD, MPH, FAASLD is a Professor of Medicine, Director of the Hepatobiliary Interest Group and Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Mayo Clinic, Rochester, Minnesota. Her clinical and research area of interest has focused on NAFLD / NASH, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials, including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH. She collaborates extensively to transition new compounds to first-in-man clinical studies and translate clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/ consultant to many industries, FDA, and biomarker development companies in the area of diagnostics and therapeutics for NASH. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a steering committee member of the NIH Liver Cirrhosis Network and a former 16-year member NASH Clinical Research Network (NASH CRN. Dr. Abdelmalek has published more than 200 manuscripts and currently serves as an Associate Editor of HEPATOLOGY, the official journal of the AASLD.
Talks About #CriticalCare #ClinicalResearch #Healthcare
Preferred Locations #NorthAmerica